Comparison of the immunogenicity and reactogenicity of two commercially available hexavalent vaccines administered as a primary vaccination course at 2, 4 and 6 months of age

Vaccine

Volumn 23, Issue 25, 2005, Pages 3272-3279

  Tichmann, I ^a   Preidel, H ^b   Grunert, D ^c   Habash, S ^d   Schult, R ^e   Maier, R ^f   Gildberg, P K ^e   Sengespeik, H C ^a   Meurice, F ^g   Sanger R ^h  

^a Arztpraxis München   (Germany)

^b Arztpraxis Olching   (Germany)

^c Arztpraxis Nördlingen   (Germany)

^d Arztpraxis Cham   (Germany)

^e Arztpraxis Flensburg   (Germany)

^f Arztpraxis Tuttlingen   (Germany)

^g GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^h GLAXOSMITHKLINE   (Germany)

Author keywords

Combined hexavalent paediatric vaccines; Diphtheria tetanus pertussis hepatitis B polio Haemophilus influenzae type b vaccines; Primary immunisation

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE;

AGE DISTRIBUTION; ANTIBODY BLOOD LEVEL; APPETITE DISORDER; BACTERIAL INFECTION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPHTHERIA; DROWSINESS; DRUG ACTIVITY; DRUG RESPONSE; DRUG SAFETY; EDEMA; ERYTHEMA; FEMALE; FEVER; HAEMOPHILUS INFLUENZAE TYPE B; HEPATITIS B; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFANT; INJECTION PAIN; INJECTION SITE REACTION; IRRITABILITY; MALE; NORMAL HUMAN; PERTUSSIS; POLIOMYELITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TETANUS; VACCINATION;

EID: 20244380489     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.01.087     Document Type: Conference Paper

References (51)

1. M.D. Decker, K.M. Edwards, M.C. Steinhoff, M.B. Rennels, M.E. Pichichero, and J.A. Englund Comparison of 13 acellular pertussis vaccines: adverse reactions Pediatrics 96 1995 557 566
2. D. Greco, S. Salmaso, P. Mastrantonio, M. Giuliano, A.E. Tozzi, and A. Anemona A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis N Engl J Med 334 1996 341 348
3. L. Gustafsson, H.O. Hallander, P. Olin, E. Reizenstein, and J. Storsaeter A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine N Engl J Med 334 1996 349 355
4. H.J. Schmitt, C.H.W. von König, A. Neiss, H. Bogaerts, H.L. Bock, and H. Schulte-Wissermann Efficacy of acellular pertussis vaccine in early childhood after household exposure J Am Med Assoc 275 1996 37 41
5. F. Simondon, M.-P. Preziosi, A. Yam, C.T. Kane, L. Chabirand, and I. Iteman A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal Vaccine 15 1997 1606 1612
6. K. Stehr, J.D. Cherry, U. Heininger, S. Schmitt-Grohe, M. Uberall, and S. Laussucq A comparative trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTaP vaccine, the Lederle whole cell component DTP vaccine or DT vaccine Pediatrics 101 1 1998 1 11
7. T. Jefferson, M. Rudin, and C. DiPietrantonj Systematic review of the effects of pertussis vaccines in children Vaccine 21 2003 2003 2014
8. Report of the Global Advisory Group. Expanded programme on immunization. Wkly Epidemiol Rec 1992;67:11-5.
9. Hepatitis B vaccine - making global progress. Expanded programme on immunization. WHO Update; 1996.
10. CDC ACIP. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Morb Mortal Wkly Rep 1991;40:1-25.
11. Recommended childhood immunization schedule - United States, 1999. Morb Mortal Wkly Rep 1999;40:12-6.
12. Updated: Recommendations to prevent hepatitis B virus transmission - United States. Morb Mortal Wkly Rep 1999;48:33-5.
13. Anon. Policy statement. Universal hepatitis B immunization. AAP News; 1992.
14. American Academy of Pediatrics. Hepatitis B. In: Peter G, editor. 1997 Red book: report of the committee on infectious diseases. 24th ed. Elk Grove village, IL: American Academy of Pediatrics; 1997. p. 247-60.
15. WHO Update 1996. CDC hepatitis B fact sheet; 2000.
16. Advisory Committee on Immunization Practices (ACIP). Revised recommendations for routine poliomyelitis vaccination. Morb Mortal Wkly Rep 1999;48:590.
17. C. Capiau, J. Poolman, B. Hoet, H. Bogaerts, and F. Andre Development and clinical testing of multivalent vaccines based on diphtheria-tetanus-acellular pertussis vaccine: difficulties encountered and lessons learned Vaccine 21 2003 2273 2287
18. Hexavac™ Product Monograph, Aventis Pasteur MSD; February 2000.
19. R. Lagos, A. Munoz, P. Fabre, E. Pines, M. Barrand, and H. Salomon Safety and immunogenicity of three lots of a liquid hexavalent vaccine given at 2, 4 and 6 months of age Proceedings of the Infectious Diseases Society of America, 37th annual meeting Philadelphia, US, 18-21 November 1999 [Abstract 663]
20. E. Mallet, P. Fabre, E. Pines, H. Salomon, T. Staub, and F. Schodel Immunogenicity and safety of a new liquid hexavalent combined vaccine compared with separate administration of reference licensed vaccines in infants Pediatr Infect Dis J 19 2000 1119 1127
21. H.J. Schmitt, M. Knuf, E. Ortiz, R. Sänger, M.C. Uwamwezi, and A. Kaufhold Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio virus and Haemophilus influenzae type b vaccines given either as separate or mixed injections J Pediatr 137 2000 304 312
22. M. Avdicova, V. Prikazsky, H. Hudeckova, L. Schuerman, and P. Willems Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule Eur J Pediatr 161 11 2002 581 587
23. J. Aristegui, R. Dal-Ré, J. Diez-Delgado, J. Mares, J.M Casanovas, and P. Garcia-Corbeira Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age Vaccine 21 2003 3593 3600
24. R. Dagan, K. Igbaria, L. Piglansky, R. Melamed, P. Willems, and A. Grossi Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine Pediatr Infect Dis J 16 1997 1113 1121
25. R. Gylca, V. Gylca, O. Benes, A. Melnic, V. Chicu, and C. Weisbecker A new DTPa-HBV-IPV vaccine co-administered with Hib, compared to a commercially available DTPw-IPV/Hib vaccine co-administered with HBV, given at 6, 10 and 14 weeks following HBV at birth Vaccine 19 2000 825 833
26. E.A. Mortimer, and M. Wharton Diphtheria toxoid S.A. Plotkin W.A. Orenstein Vaccines 3rd ed. 1999 W.B. Saunders Company Philadelphia 140 157
27. K. Miyamura, S. Nisho, A. Ito, R. Murato, and R. Kono Micro cell culture method for determination of diphtheria toxin and antitoxin titres using VERO cells: I. Studies on factors affecting the toxin and antitoxin titration J Biol Stand 2 1974 189 201
28. K. Miyamura, S. Nisho, A. Ito, R. Murata, and R. Kono Micro cell culture method for determination of diphtheria toxin and antitoxin titres using VERO cells: II. Comparison with rabbit skin method and practical application for sero epidemiological studies J Biol Stand 2 1974 203 209
29. J. Van Savage, M.D. Decker, K.M. Edwards, S.H. Sell, and D.T. Karzon Natural history of pertussis antibody in the infant and effect on vaccine response J Infect Dis 161 1990 487 492
30. B. Laubereau, M. Hermann, H.J. Schmitt, J. Weil, and R. Von Kries Detection of delayed vaccinations: a new approach to visualize vaccine uptake Epidemiol Infect 128 2002 185 192
31. Centers for Disease Control. Recommendations of the immunisation practices advisory committee. Recommendations for protection against viral hepatitis. Morb Mortal Wkly Rep 1985;34:329-35.
32. International Group. Immunization against hepatitis B. Lancet 1988;I:875-6.
33. European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Consensus statement. Lancet 2000;355:561-5.
34. ®) Proceedings of the 42nd interscience conference on antimicrobial agents and chemotherapy (ICAAC) San Diego, USA 2002
35. H.-J. Schmitt, G. Petersen, D. Laufer, and Corsaro B and the Prevenar Study Group Immunogenicity and safety of a 7-valent pneumococcal conjugate vaccine (Prevenar) coadministered with a DTaP-IPV-HBV/Hib vaccine (Infanrix™ Hexa) Proceedings of the 42nd interscience conference on antimicrobial agents and chemotherapy (ICAAC) San Diego, USA 2002
36. I. Tichmann-Schumann, P. Soemantri, U. Behre, J. Disselhoff, H. Mahler, and G. Maechler Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate vaccine Pediatr Infect Dis J 24 2005 70 77
37. A.M. Galazka, S.E. Robertson, and G.P. Oblapenko Resurgence of diphtheria Eur J Epidemiol 11 1995 95 105
38. A.M. Galazka The changing epidemiology of diphtheria in the vaccine era J Infect Dis 181 Suppl. 1 2000 S2 S9
39. Centre for Disease Control and Prevention. Respiratory diphtheria in a Pennsylvania resident recently returned from Haïti: Report underscores importance of vaccination to prevent diphtheria. http://www.phppo.cdc.gov/HAN/ archivesys/viewmsgv.asp?alertnum=00161
40. Centre for Disease Control and Prevention. Fatal respiratory diphtheria in a U.S. traveller to Haïti - Pennsylvania, 2003. http://www.cdc.gov/mmwr/ preview/mmwrhtml/mm5253a3.htm.
41. J. Storsaeter, H.O. Hallander, L. Gustafsson, and P. Olin Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis Vaccine 21 2003 3542 3549
42. J.D. Cherry, J. Gornbein, U. Heininger, and K. Stehr A search for serologic correlates of immunity to Bordetella pertussis cough illnesses Vaccine 16 1998 1901 1906
43. J. Storsaeter, H.O. Hallander, L. Gustafsson, and P. Olin Levels of antipertussis antibodies related to protection after household exposure to Bordetella pertussis Vaccine 16 1998 1907 1916
44. J.D. Cherry Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials Pediatr Infect Dis J 16 1997 S90 S96
45. E.L. Hewlett Pertussis: current concepts of pathogenesis and prevention Pediatr Infect Dis J 16 4 Suppl. 1997 S78 S84
46. E.L. Hewlett, and J.D. Cherry New and improved vaccines against pertussis M.M. Levine G.C. Woodrow J.B. Kaper G.S. Cobon New and improved vaccines against pertussis 1997 Marcel Dekker New York 387 416
47. N. Guiso, C. Capiau, G. Carletti, J. Poolman, and P. Hauser Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines Vaccine 17 1999 2366 2376
48. P. Denoël, J. Poolman, G. Carletti, and K. Veitch Effects of adsorption of acellular pertussis antigens onto different aluminium salts on the protective activity in an intranasal murine model of Bordetella pertussis infection Vaccine 20 2000 2551 2555
49. J.G. Liese, S. Stojanov, F. Berut, P. Minini, E. Harzer, and S. Jow Large scale safety study of a liquid hexavalent vaccine (D-T-acP-IPV-PRP/T-HBs) administered at 2, 4, 6 and 12-14 months of age Vaccine 20 2002 448 454
50. S. Esposito, A. Lizioli, A. Lastrico, H. Trecchi, E. Begliatti, and S. Guerci Simultaneous administration of heptavalent pneumococcal conjugate vaccine (PCV) and different diphtheria-tetanus-acellular pertussis-inactivated poliovirus-hepatitis B-Haemophilus influenzae type B (DTaP-IPV-HBV-Hib) vaccines in children Proceedings of the 43rd interscience conference on antimicrobial agents and chemotherapy (ICAAC) Chicago, IL 2003
51. F. Zepp, M. Knuf, U. Heininger, K. Jahn, A. Collard, and P. Habermehl Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants Vaccine 22 2004 2226 2233